BMS-986500 for Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called BMS-986500 for individuals with advanced breast cancer or other solid tumors. Researchers aim to evaluate the effectiveness of BMS-986500 both alone and in combination with other therapies, particularly in cases where CDK4/6 inhibitors (common breast cancer drugs) have failed. The study includes several groups to test different doses and combinations. Suitable candidates have been diagnosed with a hard-to-treat solid tumor, such as advanced breast cancer, that cannot be surgically removed. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new therapy.
Do I need to stop my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that BMS-986500 is likely to be safe for humans?
Research has shown that BMS-986500 remains in the early testing stages. In Phase 1, the primary goal is to determine the treatment's safety for people. This phase typically involves a small number of participants to closely monitor any side effects and assess how well individuals tolerate the drug.
Currently, limited information exists about BMS-986500's safety in humans, which is typical for new treatments in early study phases. However, Phase 1 trials prioritize safety. Researchers will closely monitor participants to ensure their health and safety.
For those considering joining a trial with BMS-986500, researchers will focus heavily on observing any side effects and ensuring the treatment's safety for all involved.12345Why do researchers think this study treatment might be promising?
Most treatments for breast cancer, like chemotherapy and hormonal therapies, work by killing rapidly dividing cells or blocking hormones that fuel cancer growth. But BMS-986500 works differently, targeting specific proteins involved in cancer cell signaling pathways, potentially leading to more precise treatment. Researchers are excited because this targeted approach could mean fewer side effects and improved effectiveness, especially for patients who don’t respond well to existing therapies. Plus, this treatment could open doors to new combination therapies, offering more options for personalized cancer care.
What evidence suggests that BMS-986500 might be an effective treatment for advanced breast cancer?
Research has shown that BMS-986500 is being tested for its potential to treat advanced breast cancer. This trial evaluates BMS-986500 both as a monotherapy and in combination with other treatments. Early results suggest that this drug, whether used alone or with other treatments, might benefit patients who have already tried CDK4/6 inhibitors. The drug targets specific pathways in cancer cells, potentially slowing or stopping tumor growth. Although information remains limited, the aim is to determine if BMS-986500 can offer new hope for patients with advanced solid tumors. More updates will follow as research progresses.12678
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, including breast and ovarian cancer. It's specifically for those who have tried CDK4/6 inhibitors before if they have breast cancer. Participants must be in good physical condition with acceptable organ function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986500 as monotherapy or in combination therapy, with dose escalation and expansion phases
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986500
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania